Dr. Syed Osman Ali is a cardiothoracic and thoracic surgeon at Advent Health in Orlando, Florida. He has extensive experience in thoracic surgery and in the use of pleurectomy and decortication, the lung-sparing surgery that is used to great effect in the treatment of malignant pleural mesothelioma. Dr. Ali is skilled in the use of
Malignant pleural mesothelioma is a highly aggressive cancer that is notoriously difficult to treat. Patients diagnosed with the rare asbestos-related disease generally six to 21 months after diagnosis, a survival rate that has not changed for decades. A group of researchers from the Imperial College in London investigated a novel approach to treating the disease
Dr. Joshua R. Sonett is a thoracic surgeon and oncologist at Columbia Surgery at New York-Presbyterian in New York. He is the Chief of the Thoracic Surgery Section and the Director of the Price Family Center for Comprehensive Chest Care, Lung and Esophageal Center. Dr. Sonett is credited with having made the Thoracic Surgery section
Dr. Suzanne C. Schiffman is a surgical oncologist with the Allegheny Health Network in Pittsburgh, Pennsylvania. She specializes in treating patients with malignant peritoneal mesothelioma and other complex abdominal malignancies, including cancers of the bile duct, pancreas, liver, stomach, small bowel, colon, and peritoneum. Dr. Schiffman’s surgical skills include minimally invasive techniques, as well as
Konstantinos Votanopoulos is a surgical oncologist at Wake Forest Baptist Medical Center, a Professor of Surgical Sciences and Cancer Biology at Wake Forest University School of Medicine, and a Professor at the Wake Forest Institute for Regenerative Medicine. He specializes in the use of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of abdominal
This morning, an article appeared in a respected medical journal reporting on a complete response to the immunotherapy drug pembrolizumab in a patient with malignant peritoneal mesothelioma. The case study’s authors encourage the drug’s use, despite the lack of evidence to support the treatment.
Dr. Erin P. Ward is a surgical oncologist at the University of Utah Health and the Huntsman Cancer Institute in Salt Lake City, Utah. Her clinical interests include metastatic colorectal cancer; appendiceal cancer; gastric cancer; neuroendocrine tumors; minimally invasive surgery; peritoneal mesothelioma; and peritoneal-based malignancies. She has particular expertise in the treatment of peritoneal surface
Dr. Missak Haigentz is a cancer physician and thoracic oncologist at the Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. Dr. Haigentz has focused his experience and knowledge on caring for patients with thoracic cancers including cancer of the lung and thymus, malignant pleural mesothelioma, and head and neck cancers including cancers of the
Dr. Jules Lin is a noted thoracic and surgical critical care surgeon at the University of Michigan and Rogel Cancer Center, where his areas of practice include minimally invasive and robotic surgery for the treatment of patients with lung and esophageal cancer, malignant pleural mesothelioma, and other chest wall and thoracic malignancies. Dr. Lin has
Dr. David J. Kwiatkowski is a practicing thoracic oncologist and genetic researcher with expertise in all types of thoracic malignancy. His particular interests include therapeutic targeting and personalized medicine approaches to cancer patient care. He is also a visiting scientist at the Broad Institute, where he is engaged in many cancer genome sequencing projects, including The